下载PDF
{"title":"Using Acutely Dissociated and Purified Oligodendrocyte Precursor Cells for High-Throughput Drug Screening to Identify Compounds that Promote Oligodendrocyte Differentiation","authors":"Karen Lariosa-Willingham, Dmitri Leonoudakis","doi":"10.1002/cpcb.49","DOIUrl":null,"url":null,"abstract":"<p>Multiple sclerosis (MS) is an autoimmune disease that involves an immune-mediated inflammatory response in the central nervous system and optic nerve resulting in demyelination and neural degeneration, the cause of which is unknown. The adult central nervous system has the capacity to remyelinate axons by generating new oligodendrocytes (OLs). To identify clinical candidate compounds that may promote remyelination, we have developed a high-throughput screening (HTS) assay to identify compounds that promote the differentiation of oligodendrocyte precursor cells (OPCs) into OLs. Using acutely dissociated and purified rat OPCs coupled with immunofluorescent image quantification, we have developed an OL differentiation assay. Building on OPC culturing techniques developed over the past 30 years, we have scaled up the isolation and purification process to generate sufficient quantities for HTS. We then describe the use of these acutely derived OPCs in an assay designed to identify compounds that promote differentiation into OLs. We have validated this assay with a known promoter of differentiation, thyroid hormone, and subsequently used the assay to screen the NIH clinical collection library (Lariosa-Willingham, et al., 2016). © 2018 by John Wiley & Sons, Inc.</p>","PeriodicalId":40051,"journal":{"name":"Current Protocols in Cell Biology","volume":"79 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2018-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/cpcb.49","citationCount":"4","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Protocols in Cell Biology","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cpcb.49","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Biochemistry, Genetics and Molecular Biology","Score":null,"Total":0}
引用次数: 4
引用
批量引用
Abstract
Multiple sclerosis (MS) is an autoimmune disease that involves an immune-mediated inflammatory response in the central nervous system and optic nerve resulting in demyelination and neural degeneration, the cause of which is unknown. The adult central nervous system has the capacity to remyelinate axons by generating new oligodendrocytes (OLs). To identify clinical candidate compounds that may promote remyelination, we have developed a high-throughput screening (HTS) assay to identify compounds that promote the differentiation of oligodendrocyte precursor cells (OPCs) into OLs. Using acutely dissociated and purified rat OPCs coupled with immunofluorescent image quantification, we have developed an OL differentiation assay. Building on OPC culturing techniques developed over the past 30 years, we have scaled up the isolation and purification process to generate sufficient quantities for HTS. We then describe the use of these acutely derived OPCs in an assay designed to identify compounds that promote differentiation into OLs. We have validated this assay with a known promoter of differentiation, thyroid hormone, and subsequently used the assay to screen the NIH clinical collection library (Lariosa-Willingham, et al., 2016). © 2018 by John Wiley & Sons, Inc.
利用急性分离和纯化的少突胶质前体细胞进行高通量药物筛选以鉴定促进少突胶质细胞分化的化合物
多发性硬化症(MS)是一种自身免疫性疾病,涉及中枢神经系统和视神经的免疫介导炎症反应,导致脱髓鞘和神经变性,其原因尚不清楚。成人中枢神经系统具有通过产生新的少突胶质细胞(OLs)使轴突再髓鞘化的能力。为了鉴定可能促进髓鞘再生的临床候选化合物,我们开发了一种高通量筛选(HTS)方法来鉴定促进少突胶质前体细胞(OPCs)向OLs分化的化合物。使用急性分离和纯化的大鼠OPCs结合免疫荧光图像定量,我们开发了一种OL分化试验。在过去30年开发的OPC培养技术的基础上,我们扩大了分离和纯化过程,以产生足够数量的HTS。然后,我们描述了这些急性衍生的OPCs在一项旨在识别促进分化为ol的化合物的测定中的使用。我们已经用一种已知的分化启动子甲状腺激素验证了该检测方法,并随后使用该检测方法筛选NIH临床藏书库(Lariosa-Willingham等人,2016)。©2018 by John Wiley &儿子,Inc。
本文章由计算机程序翻译,如有差异,请以英文原文为准。